French medical app company Voluntis is teaming-up with Roche Pharma France over a mobile-based therapy for breast cancer. Said therapy will be evaluated in a clinical trial in France, and will involve an app and telemedicine services to monitor patients between doctor visits.
Prescribed by care-teams as an extension of treatment, it will help patients better manage their symptoms. These symptoms will be entered manually by the patient or collected automatically through connected objects in a mobile app. The data will then be automatically analyzed and sent via Internet to the patient’s medical team, which will remotely ensure personalized follow-up. Patients will then be pushed tailored recommendations to adjust their treatment thanks to the algorithmic intelligence integrated in the heart of the mobile and cloud solution.
If everything goes as planned, Voluntis and Roche may tweak the offering to treat other cancers as well.
This isn’t the first time the two companies are partnering — previously they’ve worked on a companion software for Roche’s CoaguChek INR self-testing device.
Voluntis’ on its end have been making health apps that have focused on the areas of diabetes, hemophilia and coagulation. It has raised $29 million last spring with plans to bring its diabetes-related offerings to the United States, but the FDA approval for that product is still pending.